Harvard Medical School scientists have identified a molecular route by which a gut bacterium could help drive depression, pointing to inflammation rather than brain chemistry alone as a possible target for future treatment.Researchers studying Morganella morganii, a bacterium already associated with major depressive disorder in earlier microbiome work, found that it can transform diethanolamine, a widely used chemical found in industrial processes and some consumer-product supply chains, into unusual phospholipids that activate immune responses. Laboratory analysis showed that these modified molecules triggered inflammatory signalling, including pathways linked to interleukin-6, a cytokine repeatedly associated with depressive illness.
The findings give new weight to the gut-brain axis, a field that has moved from broad association studies towards biochemical explanations of how microbes may influence mood, immunity and neurological function. Depression affects about 280 million people globally and remains a leading cause of disability, with many patients failing to respond fully to standard therapies focused on serotonin, noradrenaline or dopamine. The Harvard work adds a mechanistic layer to a growing body of evidence suggesting that at least some cases may be shaped by immune activation originating outside the brain.
Morganella morganii is not new to clinical science. It is a Gram-negative bacterium found in the intestinal tract and has been studied in relation to inflammatory bowel disease, type 2 diabetes and opportunistic infections. Its relevance to depression emerged when microbiome comparisons showed higher prevalence in some patients with major depressive disorder. Until now, the central question was whether the bacterium was a bystander in altered gut ecosystems or an active biological contributor.
The latest work suggests a more direct role. Diethanolamine, often abbreviated as DEA, can enter human exposure routes through environmental and commercial channels. When Morganella morganii encounters the compound, it appears able to incorporate it into bacterial lipids, producing molecules unlike ordinary host or microbial fats. These altered phospholipids then interact with immune sensors, including Toll-like receptor pathways that help the body detect microbial threats. Once activated, those pathways can promote cytokine release, potentially linking microbial chemistry to systemic inflammation.
Inflammation has become one of the most closely watched areas in depression research. Elevated inflammatory markers have been found in subsets of patients, and interleukin-6 has attracted particular attention because of its relationship with stress responses, immune regulation and treatment-resistant symptoms. The Harvard findings do not mean Morganella morganii causes depression by itself, nor do they suggest that all depression is inflammatory. They indicate that a specific microbial reaction may contribute to immune conditions under which depressive symptoms can arise or worsen.
The study also helps clarify why microbiome research has produced both excitement and caution. Many earlier studies showed differences in gut bacterial composition between people with depression and healthy controls, but such studies often struggled to separate cause from consequence. Diet, medication, sleep disruption, stress, illness and lifestyle can all reshape gut microbes. By identifying a defined chemical product and its immune effect, the Harvard team has moved the discussion closer to causality, though clinical validation in large patient groups remains essential.
Therapeutic implications are still at an early stage. One possible direction is to reduce production of the inflammatory phospholipids by limiting bacterial access to precursor compounds such as DEA. Another is to target the immune cascade activated by the molecules. A third is to develop microbiome-based interventions that reduce Morganella morganii abundance or alter its metabolism without disrupting beneficial gut bacteria. Such approaches would require careful testing because the microbiome is a complex ecosystem in which removing or suppressing one organism can affect many others.
The work also reinforces the case for precision psychiatry. Depression is not a single biological condition, even when symptoms overlap. Some patients may have primarily stress-related, hormonal, genetic, inflammatory or metabolic drivers. A microbial inflammation pathway could eventually help define a subgroup of patients who may benefit from immune-modulating or microbiome-directed therapies alongside psychotherapy and conventional antidepressants.
Topics
World